ATRA — Atara Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $86.22m
- $117.89m
- $120.77m
Atara Biotherapeutics Q2 revenue falls on deferred revenue recognition
Brief: Atara Biotherapeutics Q2 EPS USD -0.32
Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a share - Earnings Preview
Brief: Atara Biotherapeutics - May Offer Up To $79.27 Million In Common Stock As Of May 12, 2026 - SEC Filing
Atara Biotherapeutics Q1 revenue drops after prior-year one-time gain
Brief: Atara Biotherapeutics Q1 EPS USD -0.29
NASDAQ RESUMED AT 03:40 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:30 PM
Atara more than doubles after FDA backs re-submission of cancer drug application
U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise
NASDAQ RESUMED AT 12:19 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:14 PM
U.S. STOCKS ON THE MOVE-Albemarle, Howmet, Travere Therapeutics
NASDAQ RESUMED AT 10:55 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:50 AM
Atara jumps after US FDA backs re-submission of cancer drug application
Brief: Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel
Brief: Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel
U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners